Cas:915920-86-4 3-(1,2,4-triazol-1-yl)adamantan-1-amine manufacturer & supplier

We serve Chemical Name:3-(1,2,4-triazol-1-yl)adamantan-1-amine CAS:915920-86-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-(1,2,4-triazol-1-yl)adamantan-1-amine

Chemical Name:3-(1,2,4-triazol-1-yl)adamantan-1-amine
CAS.NO:915920-86-4
Synonyms:3-(1,2,4-triazol-1-yl)adamantan-1-amine
Molecular Formula:C12H18N4
Molecular Weight:218.29800
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:370.8ºC at 760 mmHg
Density:1.56g/cm3
Index of Refraction:1.819
PSA:56.73000
Exact Mass:218.15300
LogP:1.98500

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-(1,2,4-triazol-1-yl)adamantan-1-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(1,2,4-triazol-1-yl)adamantan-1-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(1,2,4-triazol-1-yl)adamantan-1-amine Use and application,3-(1,2,4-triazol-1-yl)adamantan-1-amine technical grade,usp/ep/jp grade.


Related News: In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum. 3-(1,2,4-triazol-1-yl)adamantan-1-amine manufacturer This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. 3-(1,2,4-triazol-1-yl)adamantan-1-amine supplier This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. 3-(1,2,4-triazol-1-yl)adamantan-1-amine vendor Looking after their staff: Airlines are under pressure from their staff, who obviously want to protect themselves. 3-(1,2,4-triazol-1-yl)adamantan-1-amine factory The findings were published June 14 in the journal Nature Aging.